MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc.(Sunovion) announced today that new clinical and health economics and outcomes research (HEOR) data for Aptiom® (eslicarbazepine acetate) will be presented at the 69th Annual Meeting of the American Epilepsy Society (AES), taking place December 4 - 8, 2015 in Philadelphia. Noteworthy presentations include research highlighting the use of APTIOM as monotherapy and adjunctive treatment of partial-onset seizures.
